Arix Bioscience plc: Harpoon Announces Proposed Public Offering in the United States

Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company
supporting medical innovation, today notes that its portfolio company Harpoon Therapeutics,
 Inc. ("Harpoon") has filed a registration statement on Form S-1 with the U.S. Securities
and Exchange Commission (the "SEC") relating to a proposed underwritten initial public
offering in the United States of shares of Harpoon's common stock.

    A registration statement relating to these securities has been filed with the SEC, but
has not yet become effective. These securities may not be sold, nor may offers to buy be
accepted, prior to the time the registration statement becomes effective. The registration
statement can be accessed through the SEC's EDGAR database.

    This announcement does not constitute an offer to sell or the solicitation of an offer
to buy securities, and shall not constitute an offer, solicitation or sale in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that state or jurisdiction.

    These securities are to be offered only by means of a prospectus. When available,
copies of the preliminary prospectus can be obtained from: Citigroup Global Markets Inc.,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at (800) 831-9146 ; or Leerink Partners LLC, Attention: Syndicate Department,
One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext.
6132, or by e-mail at [email protected]. For the avoidance of doubt, such prospectus
will not constitute a "prospectus" for the purposes of Directive 2003/71/EC (and
amendments thereto, including Directive 2010/73/EU, to the extent implemented in each
relevant EU member state) and will not have been reviewed by any competent authority in
any EU member state.

    About Arix Bioscience plc 

    Arix Bioscience plc is a global healthcare and life science company supporting medical
innovation. Headquartered in London and with an office in New York, Arix Bioscience
sources, finances and builds world class healthcare and life science businesses addressing
medical innovation at all stages of development. Operations are supported by privileged
access to breakthrough academic science and strategic relationships with leading research
accelerators and global pharmaceutical companies.

    Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

    About Harpoon Therapeutics, Inc 

    Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel
class of T cell engagers that harness the power of the body's immune system to treat
patients suffering from cancer and other diseases. T cell engagers are engineered proteins
that direct a patient's own T cells to kill target cells that express specific proteins,
or antigens, carried by the target cells. Using its proprietary Tri-specific T cell
Activating Construct(TM) ("TriTAC"), platform, Harpoon is developing a pipeline of novel T
cell engagers, or TriTACs, initially focused on the treatment of solid tumors and
hematologic malignancies. Harpoon recently announced its second technology platform,
ProTriTAC, that applies a prodrug concept to TriTAC in order to create T cell engagers
that are designed to be preferentially active in the tumor microenvironment.

        PRN NLD



The content and accuracy of news releases published on this site and/or
distributed by PR Newswire or its partners are the sole responsibility of the
originating company or organisation. Whilst every effort is made to ensure the
accuracy of our services, such releases are not actively monitored or reviewed
by PR Newswire or its partners and under no circumstances shall PR Newswire or
its partners be liable for any loss or damage resulting from the use of such
information. All information should be checked prior to publication.